Autoimmune diseases

FT819 Remodels Lupus B Cells in Clinical Trial
CMN Briefs

May. 13, 2026

Updated Phase 1 data presented at the 2026 American Society of Gene and Cell Therapy (ASGCT) meeting suggest that Fate Therapeutics’ off-the-shelf CAR...

Highlight: CRISPR Gene Editing Exposes Hidden...
CMN Special

Oct. 8, 2025

Researchers in the UK have utilised precision gene editing to identify a regulatory element concealed within a gene associated with several autoimmune...

Allogene's Dual-Acting CAR T Candidate ALLO-329...
CMN Clinical

Jan. 29, 2025

The FDA has cleared Allogene Therapeutics' IND application for ALLO-329, a novel dual-targeting CAR T cell therapy designed to treat multiple...

Autoimmune diseases

Refractory Systemic Lupus Erythematosus, SLE, (NCT07083349)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
Multiple Sclerosis, (NCT07008378)
Sponsors:
Genentech, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Refractory Autoimmune Disease, (NCT06925542)
Sponsors:
CRISPR Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
Systemic Lupus Erythematosus, SLE, (NCT06752876)
Sponsors:
Caribou Biosciences, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Lupus Nephritis, (NCT06681337)
Sponsors:
Bioray Laboratories
Indicator
IND Enabling
Phase I
Phase II
Phase III
Neuromyelitis Optica Spectrum Disease, NMOSD, (NCT06633042)
Sponsors:
Bioray Laboratories
Indicator
IND Enabling
Phase I
Phase II
Phase III
Systemic Lupus Erythematosus, SLE, (NCT06373991)
Sponsors:
EdiGene Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Refractory Autoimmune Diseases, (NCT06485232)
Sponsors:
Xuanwu Hospital, Beijing
Indicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine